In this podcast we feature an article that looks at the near-term and long-term impact of the COVID-19 pandemic as biopharma companies re-access drug-development projects.  For a text version of this article visit dcatvci.org.

Key topics: (see Chapter Markers)

• The CDMO industry in the wake of COVID-19
• Near-term outlook
• Medium-term could be challenging
• Longer-term implications